Math Biology

Math Biology® - Overview

Math Biology® is an AI-based health-tech company developing DMA® (Deep Metabolic-process Assessment), a non-invasive platform that turns bioelectrical signals into structured metabolic information.

Who benefits

• Athletes & coaches: metabolic insight on readiness, training load, and recovery, delivered in a single session.

• Longevity & wellness clients: non-invasive, repeatable tracking of metabolic wellbeing over time.

• Clinicians & Patients: objective, complementary information that supports health assessment, early diagnosies and decisions on further investigation.

• Clinics, pharmacies & performance centers: a new recurring service line that integrates into existing facilities.

• Payers & employers (2027+): a scalable, low-cost tool for prevention programs and risk-pool management.

Key questions, short answers

What problem do we solve?
Healthcare remains reactive, episodic, and often invasive, and it can take weeks to see whether an intervention is working.

What outcome do we improve?
DMA® compresses time-to-answer into one 15–60 minute visit, measures up to 600 bio-parameters, at a reasonable costs per visit.

What proof do we have?

• The evidence base includes 2M+ data points, 25,000+ protocols, and 1,300+ subjects in a retrospective dataset.

• In exploratory analysis, BMRi separated healthy controls from untreated oncology patients by more than 4×.

• Three prospective studies are active: Oncology, Cardiology, and Infections.

Who pays?

• Near term: sport clubs and longevity clinics, paying cash.

• Mid term: clinics and pharmacies, through a Technology-as-a-Service (TaaS) subscription.

• Long term: insurers and self-insured employers.

What traction do we have?

• An anchor community of about 500 patients for the first flagship Human Biology Institute (HBI) - our data Lab: visit, Demo training & continuous Research Medical Center.

• Advanced talks & tests with tennis club clusters totaling about 7,200 members.

• Research frameworks with the CNR (Italian National Research Center), University of Salerno and Campus Bio-Medico.

Why us, and why now?
DMA® is the only non-invasive platform assessing multi-organ metabolic function, including neurotransmitter metabolic demand, in a single visit. It is protected by passive-acquisition physics, a library of 100+ protocols, a growing data flywheel, and 3 pending patents.

How do we go to market?

• Phase 1: cash-pay sport and longevity, with sales cycles of weeks.

• Phase 2: hosted HBIs in clinics and pharmacies, funded by franchise partners.

• Phase 3: integration with payers.

How are we de-risked?
Sport and longevity revenue does not depend on reimbursement or FDA clearance. EU MDR Class I conformity and the ISO 13485 QMS complete in October 2026 [confirm vs. "reached" in memo].

What do we raise, and for what?
[€12M Series A / Seed+ SAFE at a $48M cap — confirm]

• 35% clinical validation and regulatory

• 30% go-to-market and flagship HBIs

• 25% team and US expansion

• 10% IP, QMS, and working capital

The technology

DMA® combines biology, physics, engineering, and mathematical modeling. It passively acquires the nanoampere-range bioelectrical signals the body emits naturally; no current is injected. Acquisition follows a standardized 61-point protocol [61 vs. 62 in memo — align]. A single visit measures up to 600 bio-parameters. The full protocol library covers 1,500+ biomarkers and can be extended to new investigation areas. Proprietary AI models in a secure cloud compute the Bioelectrical Marker Response Index (BMRi), a quantitative indicator of metabolic activation or dysregulation.

Product lines & Regulatory Pathways

• DMA® Performance (General Wellness), ready: for sport and longevity.

• DMA® Screening (EU MDR Class I), ready: auxiliary metabolic information.

• DMA® Diagnostics (EU MDR Class IIa / FDA), in development: an adjunct to clinical diagnosis.

Who is the team?

• Pharma R&D depth from a former Pfizer R&D Director.

• AI and mathematical modeling leadership from a founder with a prior exit.

• Finance, legal, and regulatory leads, plus US advisors.